New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
07:55 EDTLXRXLexicon removed from Stifel Select List at Stifel
Stifel removed Lexicon from its Select List, citing what it sees as a lack of near-term data catalysts and limited visibility into a partnership for LX4211. The firm thinks the company is favorably positioned for a partnership, but that it's difficult to predict the timing of such a deal. It keeps a $4 price target and Buy rating on the shares.
News For LXRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
08:03 EDTLXRXLexicon announces first patient screened in Phase 3 trial of sotagliflozin
Lexicon announced that it has commenced screening in its first pivotal Phase 3 clinical trial of sotagliflozin for type 1 diabetes. Lexicon will be conducting two pivotal Phase 3 clinical trials of sotagliflozin, one in North America and another primarily in Europe. Each pivotal trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of sotagliflozin in adult patients with type 1 diabetes. Two dose levels of sotagliflozin, 200mg and 400mg once daily, will be tested along with placebo. The primary efficacy endpoint under evaluation will be reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7%, reduction in meal-time, or bolus, insulin use and weight loss.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use